Form 4: Collegium Pharmaceutical Director Bohlin Exercises Options and Sells Shares

Director Garen G. Bohlin of Collegium Pharmaceutical, Inc. exercised stock options and sold shares, while also receiving a grant of restricted stock units.

Summary

• On May 14, 2024, Garen G. Bohlin, a director of Collegium Pharmaceutical, Inc., exercised stock options to acquire 28,985 shares of common stock at a price of $5.73 per share.
• On the same day, Bohlin sold 28,985 shares of common stock at a weighted average price of $32.3033, with prices ranging from $32.00 to $32.80.
• On May 16, 2024, Bohlin was granted 7,693 restricted stock units (RSUs) that will vest on May 16, 2025, contingent upon continued service as a director.
• Following these transactions, Bohlin beneficially owns 52,468 shares of Collegium Pharmaceutical, Inc. common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as the filing simply reports transactions. The exercise of options and sale of shares could be interpreted in various ways, but without additional context, it's difficult to assign a strong positive or negative sentiment.

Positives

• The grant of restricted stock units (RSUs) aligns the director's interests with the long-term performance of the company.

Future Outlook

The vesting of the RSUs is contingent upon the director's continued service with the Issuer, indicating an expectation of ongoing involvement.

Industry Context

Form 4 filings are routine disclosures of insider transactions, providing transparency to investors about the buying and selling activities of company insiders. These filings are closely watched as they can provide signals about management's view of the company's prospects.

Comparison to Industry Standards

• Insider transactions are common across publicly traded companies, and the details of these transactions are often compared to those of peer companies to gauge sentiment.
• For example, similar transactions can be seen in companies like Teva Pharmaceutical Industries Ltd. and Viatris Inc., where directors and officers regularly buy or sell shares and receive stock options or RSUs as part of their compensation packages.
• The vesting schedules and exercise prices are often benchmarked against industry standards to ensure they are competitive and aligned with shareholder interests.

Stakeholder Impact

• Shareholders may interpret the director's sale of shares as a signal, although it's important to consider the context of the option exercise and RSU grant.
• The transactions have no immediate impact on employees, customers, suppliers, or creditors.

Key Dates